Analyzing Unicycive Therapeutics (NASDAQ:UNCY) & Siga Technologies (NASDAQ:SIGA)
by Danessa Lincoln · The Markets DailySiga Technologies (NASDAQ:SIGA – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Siga Technologies and Unicycive Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Siga Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Unicycive Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
Unicycive Therapeutics has a consensus price target of $18.75, indicating a potential upside of 261.27%. Given Unicycive Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Siga Technologies.
Valuation & Earnings
This table compares Siga Technologies and Unicycive Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Siga Technologies | $53.66 million | 4.30 | $23.28 million | ($0.05) | -64.20 |
| Unicycive Therapeutics | $680,000.00 | 212.56 | -$26.56 million | ($1.75) | -2.97 |
Siga Technologies has higher revenue and earnings than Unicycive Therapeutics. Siga Technologies is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 2.7% of Siga Technologies shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Siga Technologies has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500.
Profitability
This table compares Siga Technologies and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Siga Technologies | -5.19% | -1.55% | -1.32% |
| Unicycive Therapeutics | N/A | -91.50% | -61.47% |
Summary
Unicycive Therapeutics beats Siga Technologies on 8 of the 14 factors compared between the two stocks.
About Siga Technologies
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.